NCT01138085 - Safety, Pharmacokinetics (PK) of AKT and MEK Combination | Biotech Hunter

Enrollment

240

Participants

Timeline

Start Date

May 4, 2010

Primary Completion Date

November 19, 2014

Study Completion Date

November 19, 2014

Conditions

Cancer

Interventions

DRUG

GSK1120212

MEK inhibitor

DRUG

GSK2141795

AKT Inhibitor

Trial Locations (10)

GSK Investigational Site, Nashville

GSK Investigational Site, Dallas

GSK Investigational Site, San Antonio

GSK Investigational Site, Aurora

GSK Investigational Site, New Haven

GSK Investigational Site, Boston

GSK Investigational Site, Boston

GSK Investigational Site, New Brunswick

GSK Investigational Site, Houston

GSK Investigational Site, Salt Lake City